Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying of a novel RUNX1-RARA fusion in variant acute promyelocytic leukemia

ABSTRACT: Identifying of a novel RUNX1-RARA fusion in variant acute promyelocytic leukemia

PROVIDER: PRJNA1164207 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30769918_1.fastq.gz	Fastqsanger.gz
	SRR30769918_2.fastq.gz	Fastqsanger.gz
	SRR30769919_1.fastq.gz	Fastqsanger.gz
	SRR30769919_2.fastq.gz	Fastqsanger.gz
	SRR30769920_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Identifying of a novel RUNX1-RARA fusion in variant acute promyelocytic leukemia

Project description:Here we report a novel fusion gene, RUNX1-RARA, in acute promyelocytic leukemia (APL). RUNX1-RARA triggers APL genesis by mediating transcriptional repression of target genes, and it can be potently restrained by all-trans retinoic acid treatment.

2024-09-28 | GSE277794 | GEO

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

Project description:Here we report a new fusion gene, STRN3-RARA, in acute promyelocytic leukemia (APL). It cooperates with UTX deficiency to drive full-blown APL in mice. Although STRN3-RARA leukemia quickly relapses after all-trans retinoic acid treatment, it can be restrained by cepharanthine.

2024-04-23 | GSE224816 | GEO

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

Project description:Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

| PRJNA932745 | ENA

PML-RARA fusion gene requires Dnmt3a to induce acute promyelocytic leukemia in mice

Project description:Loss of function mutations in the DNA methyltransferase DNMT3A are highly recurrent in acute myeloid leukemia (AML). DNMT3A and DNMT3B encode the two methyltransferases that are primarily responsible for the de novo methylation of specific DNA sequences during cellular differentiation. DNMT3A mutations are rarely found in AML patients with translocations that create oncogenic fusion genes (e.g. PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11, and MLL-X). To begin to define the reasons why these mutations do not occur together, we used retroviral vectors to express PML-RARA, RUNX1-RUNX1T1, and MLL-AF9 in the bone marrow cells of wild type (WT) or Dnmt3a deficient mice; we also examined the hematopoietic phenotypes of Ctsg-PML-RARA animals (which express PML-RARA in early hematopoietic progenitors and myeloid precursors) with and without Dnmt3a. We demonstrated that the methyltransferase activity of Dnmt3a (but not Dnmt3b) is required for aberrant self-renewal ex vivo that is driven by PML-RARA (but not RUNX1-RUNX1T1 or MLL-AF9); furthermore, the PML-RARA-driven competitive transplantation advantage and leukemia generation both required Dnmt3a. Together, these findings demonstrate that PML-RARA is specifically dependent on Dnmt3a to initiate APL in mice, and may explain why loss-of-function DNMT3A mutations are not found in patients with acute promyelocytic leukemia.

2015-10-01 | GSE68844 | GEO

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq]

Project description:Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex called the striatin-interacting phosphatase and kinase (STRIPAK), which couples kinases to protein phosphatase 2A and regulates their activities. Like other APL patients with RARA-variants, this patient quickly relapsed after the initial response to all-trans retinoic acid (ATRA) treatment. Mechanistically, we demonstrated that STRN3-RARA, in cooperating with UTX deficiency, which was mutated in the patient, drove APL formation in mice. Additionally, we found that STRN3-RARA cells were specifically susceptible to the TNFα pathway. Inhibition of this pathway by cepharanthine, an FDA-approved drug, effectively suppressed the growth of U937 cells with STRN3-RARA expression, as well as relapsed APL cells from the patient. Taken together, our study identified a new APL fusion gene, STRN3-RARA, and validated it as a functional APL driver, providing insight into the diagnosis and treatment of non-classic APL patients.

2024-04-23 | GSE224815 | GEO

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [CUT&TAG]

2024-04-23 | GSE224813 | GEO

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq 2]

2024-04-23 | GSE239350 | GEO

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq]

Project description:Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq]

| PRJNA934520 | ENA

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [CUT&TAG]

Project description:Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [CUT&TAG]

| PRJNA934521 | ENA

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq 2]